Impact



"$2 Test Could Transform Sickle Cell Dx in Africa"

December 13, 2018

"An inexpensive, easy-to-use blood test could dramatically alter how sickle cell disease is diagnosed in Africa, where the often-undiagnosed disease is a leading cause of childhood mortality, according to a manufacturer-sponsored study presented here."

Read More

"New Sickle Cell Test Can Transform Screening"

December 13, 2018

 
  
 "A new test that costs less than $2, requires only a small drop of blood, and can be performed in about 10 minutes could dramatically change the dynamics of sickle cell diagnosis in Africa, say researchers who developed the product."
Read More

HemoTypeSC Presented in Late-Breaking Abstract

December 13, 2018

"A trial in Uganda showed a new test called HemoTypeSCTM was more than 99 percent accurate in detecting sickle cell disease in young children. The test requires only a small drop of blood and returns results in about 10 minutes, making it suitable for routine screening of newborns."
Read More

Lack of Funds Hinders Govt’s Policy on SCD

December 13, 2018

Dr. Alayo Sopekan, National Desk Officer, Ministry of Health, said: “Nigeria has the highest burden of Sickle Cell Disease (SCD) in the world ahead of Democratic Republic of Congo and India.”  He called for early diagnosis and treatment of the disease.

Read More

Nigerian Health Ministry Introduces POC Testing

January 30, 2018

Video: Nigerian officials reveal how the country loses over 150,000 newborns to sickle cell disease every year. OakTV presents a report on the accuracy of HemoTypeSC™, a 10 minute investigational test kit. 

Read More

Experts Advocate Newborn Screening for Sickle Cell

January 30, 2018

Video: Professor Obiageli Nnodu, sickle cell disease expert from the University of Abuja, describes the current status of sickle cell disease in Nigeria and the results from early testing with HemoTypeSC™.

Read More





HemoTypeSC™ has a CE Mark

The HemoTypeSC™ test has received the CE Mark, which is a certification that indicates conformity with health and safety standards set by the European Economic Area (EEA).  HemoTypeSC™ is thus commercially available as an IVD in the EEA, and the CE Mark will facilitate availability of the test to all African and Indian populations that need it most.